靶向治疗配合化疗治疗肺癌脑转移患者的临床研究  

Clinical study of targeted therapy combined with chemotherapy in the treatment of lung cancer patients with brain metastases

作　　者：胡云龙 Hu Yunlong(Department of Radiotherapy, Taian Cancer Center, Taian Shandong, 271000, China)

机构地区：[1]泰安市肿瘤防治院放疗科,山东泰安271000

出　　处：《中外女性健康研究》2021年第21期3-4,共2页Women＇s Health Research

摘　　要：目的分析靶向治疗配合化疗应用于肺癌脑转移患者治疗的临床疗效。方法选本院肺癌脑转移患者90例。随机分成施行单纯化疗治疗的对照组,以及施行靶向治疗联合化疗的研究组,比较组间干预效果。结果治疗后,研究组疾病治疗控制率明显高于对照组,差异显著,而研究组发生骨髓抑制、消化道反应等不良症状较少,低于对照组,差异在统计学上有意义(P<0.05)。比较两组患者的随访生存率,发现研究组的预后较优于对照组,延长了患者的生存期,差异在统计学上有意义(P<0.05)。结论将靶向治疗配合化疗应用于肺癌脑转移患者治疗效果确切,不良反应发生较少,同时可明显改善患者的预后,因此对于肺癌脑转移患者可推荐靶向治疗配合化疗进行治疗。Objective:To analyze the clinical efficacy of targeted therapy combined with chemotherapy in the treatment of patients with lung cancer brain metastases.Methods:Ninety patients with brain metastases from lung cancer in our hospital were selected.They were randomly divided into a control group with chemotherapy alone and a study group with targeted therapy combined with chemotherapy to compare the effects of intervention between the groups.Results:After treatment,the disease treatment control rate of the study group was significantly higher than that of the control group,and the incidence of complications was significantly lower than that of the control group.The difference was significant(P<0.05).Comparing the follow-up survival rates of the two groups of patients,it was found that the prognosis of the study group was better than that of the control group,and the survival period of the patients was prolonged.The difference was statistically significant(P<0.05).Conclusion:Targeted therapy combined with chemotherapy for patients with lung cancer brain metastases has a definite effect,with fewer adverse reactions,and can significantly improve the prognosis of patients.Therefore,targeted therapy combined with chemotherapy can be recommended for patients with lung cancer brain metastases.

关 键 词：肺癌脑转移 靶向治疗 化疗 疾病控制 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]